glp 1 reduce inflammation Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent Glucagon-like peptide-1 receptor: mechanisms and

Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity

Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they

Its frustrating to watch, given my field of study.

Our very own Brian Woods breaks down what employers should do now

Type 2 diabetes (T2D) is among the most prevalent chronic metabolic disorders worldwide - driven by insulin resistance, pancreatic dysfunction, obesity, and unhealthy lifestyles